UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Monitoring the HIV-infected patient with chronic hepatitis B virus infection

Authors
Kenneth E Sherman, MD, PhD
Chloe L Thio, MD
Section Editor
David L Thomas, MD
Deputy Editor
Jennifer Mitty, MD, MPH

INTRODUCTION

The era of potent antiretroviral therapy has led to declining rates of opportunistic infections and a new focus on other leading causes of morbidity, such as end-stage liver disease secondary to chronic hepatitis B virus (HBV) infection [1]. The treatment and prevention of hepatitis B has taken on great significance in light of the negative impact HIV has on the natural history of chronic hepatitis B infection. Patients with chronic HBV and HIV coinfection should be treated with a regimen that is effective against both HIV and HBV.

However, treatment of HBV in the HIV-infected patient can be complicated by drug-induced hepatotoxicity, immune constitution syndromes, and toxicity related to medications. Furthermore, regardless of whether the patient is treated, surveillance for development of hepatocellular carcinoma is required.

Monitoring of the patient with HIV/HBV coinfection, regardless of whether the patient is taking antiviral therapy, will be discussed here. The epidemiology, clinical manifestations, diagnosis, management, and prevention of HBV infection are discussed separately. (See "Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient" and "Pretreatment evaluation of chronic hepatitis B virus infection in the HIV-infected patient" and "Treatment of chronic hepatitis B in the HIV-infected patient" and "Prevention of hepatitis B virus infection in the HIV-infected adult".)

PATIENT MONITORING DURING HBV THERAPY

HBV DNA and aminotransferase monitoring — Laboratory monitoring during hepatitis B virus (HBV) therapy includes serial aminotransferases and assessment of viral suppression. We typically monitor HBV DNA and aminotransferases every three months until undetectable for at least two consecutive visits. We then decrease the frequency to every six months.

Studies in patients with HBV alone have demonstrated that normalization of aminotransferases and suppression of HBV DNA (with or without HBeAg seroconversion) are associated with improvements in liver histology and lower rates of cirrhosis, hepatic decompensation, and hepatocellular carcinoma [2]. Studies in coinfection suggest similar benefit [3].

               
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Sep 28, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632.
  2. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009; 49:S112.
  3. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718.
  4. Soriano V, Barreiro P, Martín-Carbonero L, et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J Infect Dis 2007; 195:1181.
  5. Collins JM, Raphael KL, Terry C, et al. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin Infect Dis 2015; 61:1304.
  6. Singh KP, Crane M, Audsley J, et al. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS 2017; 31:2035.
  7. Sulkowski MS, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18:2277.
  8. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182.
  9. Soriano V, Puoti M, Garcia-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1.
  10. Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28:1032.
  11. Nowak MA, Bonhoeffer S, Hill AM, et al. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93:4398.
  12. Günther S, Fischer L, Pult I, et al. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52:25.
  13. Margeridon-Thermet S, Shulman NS, Ahmed A, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 2009; 199:1275.
  14. Locarnini S, Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther 2007; 12 Suppl 3:H15.
  15. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on September 27, 2017).
  16. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 2016; 316:191.